Slide 1

Project 1:

Host: Institute for Medical Genetics and applied Genomics, University of Tuebingen

PI: Dr. Thorsten Schmidt

More info

Slide 2
Slide 3

Project 3:

Host: Institut Curie

PI: Frédérick Saudou

More info

Slide 4
Slide 5

Project 5:

Host: Laboratoire d' Enzymologie et Biochimie Structurales - UPR 3082 CNRS

PI: Ronald Melki

More info

Slide 6
Slide 7

Project 7:

Host: University of Cambridge

PI: David Rubinsztein

More info

Slide 8
Slide 9

Project 9:

Host: University of Coimbra

PI: Luis Perreira de Almeida

More info

Slide 10
Slide 11

Project 11:

Host: Siena Biotech

PI: Andrea Caricasole

More info

Slide 12
Slide 13

Project 13:

Host: Lund University

PI: Angela Cenci-Nilsson

More info

Slide 14
Example Frame

Protein aggregation is a hallmark of many late onset neurodegenerative disorders including Parkinson’s Disease (PD), Alzheimer’s Disease (AD), amylotrophic lateral sclerosis (ALS), prion diseases as well as the group of polyglutamine diseases (polyQ). The aim of this project is to create a network of European partners bridging important basic mechanisms involved in proteinopathies, research of model diseases and treatment approaches.

The “TreatPolyQ” network will focus on two main representatives of the polyQ diseases: Huntington’s disease as the most common polyQ disease as well as spinocerebellar ataxia type 3 (SCA3) as the most frequent autosomal-dominantly inherited ataxia. Patients suffer from a multitude of neurological symptoms including movement abnormalities with late onset and in a progressive manner. Up to now, no treatment or cure is available. The network not only focuses on one special aspect of a disease but spans several important disease-associated mechanism as well as promising treatment strategies for HD and SCA3, likely to be important across a range of neurodegenerative diseases.

 

Moving Beyond ended on February, 28 2015.
Click here for a synopsis of the network activities.
TreatPolyQ is funded from the European Community‘s Seventh Framework Programme FP7/2010 under Grant Agreement No. 264508
Marie Curie Actions Logo